LOWENSTEIN MEDICAL FRANCE : revenue, balance sheet and financial ratios

LOWENSTEIN MEDICAL FRANCE is a French company founded 30 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in MASSY (91300), this company of category PME shows in 2022 a revenue of 39.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LOWENSTEIN MEDICAL FRANCE (SIREN 407518828)
Indicator 2022 2021 2020 2019 2018 2017 2016
Revenue 39 743 390 € 27 257 497 € 20 003 192 € 19 070 354 € 15 840 159 € 13 757 160 € 13 340 760 €
Net income 2 820 510 € 1 070 110 € 305 565 € 5 288 € 105 748 € 124 155 € 156 328 €
EBITDA 3 960 905 € 1 585 597 € 520 502 € -132 779 € -123 933 € 190 003 € 291 816 €
Net margin 7.1% 3.9% 1.5% 0.0% 0.7% 0.9% 1.2%

Revenue and income statement

In 2022, LOWENSTEIN MEDICAL FRANCE achieves revenue of 39.7 M€. Over the period 2016-2022, the company shows strong growth with a CAGR (compound annual growth rate) of +20.0%. Vs 2021, growth of +46% (27.3 M€ -> 39.7 M€). After deducting consumption (28.3 M€), gross margin stands at 11.5 M€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 4.0 M€, representing 10.0% of revenue. Positive scissor effect: EBITDA margin improves by +4.1 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.8 M€, i.e. 7.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2022) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

39 743 390 €

Gross margin (2022) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

11 489 933 €

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

3 960 905 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

3 906 437 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

2 820 510 €

EBITDA margin (2022) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

10.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 40%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 7.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1.943%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

39.939%

Cash flow / Revenue (2022) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

7.258%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.043

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

56.2%

Solvency indicators evolution
LOWENSTEIN MEDICAL FRANCE

Sector positioning

Debt ratio
1.94 2022
2020
2021
2022
Q1: 0.0
Med: 6.23
Q3: 53.97
Good +7 pts over 3 years

In 2022, the debt ratio of LOWENSTEIN MEDICAL FRANCE (1.94) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
39.94% 2022
2020
2021
2022
Q1: 15.33%
Med: 37.18%
Q3: 59.34%
Good +15 pts over 3 years

In 2022, the financial autonomy of LOWENSTEIN MEDICAL FRANCE (39.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.04 years 2022
2020
2021
2022
Q1: 0.0 years
Med: 0.01 years
Q3: 1.6 years
Average

In 2022, the repayment capacity of LOWENSTEIN MEDICAL FRANCE (0.04) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 163.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

163.175

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.01

Liquidity indicators evolution
LOWENSTEIN MEDICAL FRANCE

Sector positioning

Liquidity ratio
163.18 2022
2020
2021
2022
Q1: 136.77
Med: 203.41
Q3: 332.18
Average +12 pts over 3 years

In 2022, the liquidity ratio of LOWENSTEIN MEDICAL FRANCE (163.18) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
0.01x 2022
2020
2021
2022
Q1: 0.0x
Med: 0.34x
Q3: 4.26x
Average -6 pts over 3 years

In 2022, the interest coverage of LOWENSTEIN MEDICAL FRANCE (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 60 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 72 days. Favorable situation: supplier credit is longer than customer credit by 12 days. Inventory turnover is 64 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 110 days of revenue, i.e. 12.1 M€ to permanently finance. Over 2016-2022, WCR increased by +207%, requiring additional financing.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

12 125 708 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

60 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

72 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

64 j

WCR in days of revenue (2022) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

110 j

WCR and payment terms evolution
LOWENSTEIN MEDICAL FRANCE

Positioning of LOWENSTEIN MEDICAL FRANCE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of LOWENSTEIN MEDICAL FRANCE is estimated at 4 396 727 € (range 2 212 379€ - 14 457 611€). With an EBITDA of 3 960 905€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
124 transactions
2212k€ 4396k€ 14457k€
4 396 727 € Range: 2 212 379€ - 14 457 611€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
3 960 905 € × 0.7x
Estimation 2 788 022 €
1 317 997€ - 10 147 383€
Revenue Multiple 30%
39 743 390 € × 0.21x
Estimation 8 464 325 €
4 590 003€ - 25 638 579€
Net Income Multiple 20%
2 820 510 € × 0.8x
Estimation 2 317 093 €
881 902€ - 8 461 730€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare LOWENSTEIN MEDICAL FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about LOWENSTEIN MEDICAL FRANCE

What is the revenue of LOWENSTEIN MEDICAL FRANCE ?

The revenue of LOWENSTEIN MEDICAL FRANCE in 2022 is 39.7 M€.

Is LOWENSTEIN MEDICAL FRANCE profitable?

Yes, LOWENSTEIN MEDICAL FRANCE generated a net profit of 2.8 M€ in 2022.

Where is the headquarters of LOWENSTEIN MEDICAL FRANCE ?

The headquarters of LOWENSTEIN MEDICAL FRANCE is located in MASSY (91300), in the department Essonne.

Where to find the tax return of LOWENSTEIN MEDICAL FRANCE ?

The tax return of LOWENSTEIN MEDICAL FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LOWENSTEIN MEDICAL FRANCE operate?

LOWENSTEIN MEDICAL FRANCE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.